Announcement PDF Appendix 3Y Change of Director’s Interest Notice Rule 3.19A.2 Appendix 3Y Change of Director’s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/09/01 Amended 01/01/11 Name of entity Antisense Therapeutics Limited (ASX: ANP) ABN 41 095 060 745 We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act. Name of Director Ben Gil Price Date of last notice 7 October 2022 Part 1 - Change of director’s relevant interests in securities In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part. Direct or indirect interest Direct Nature of indirect interest (including registered holder) - Date of change 22 to 26 September 2023 Note: Provide details of the circumstances giving rise to the relevant interest. No. of securities held prior to change Direct Indirect Total Class Number acquired + See chapter 19 for defined terms. 01/01/2011 Shares Options 599,805 599,805 1,000,000 1,000,000 Fully Paid Ordinary Shares Direct Indirect Total Shares 400,000 400,000 Options - Appendix 3Y Page 1 Appendix 3Y Change of Director’s Interest Notice Number disposed Direct Indirect Total Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation Direct Indirect Total Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back Options - Shares Options $0.071 average No. of securities held after change Nature of change Shares - 999,805 999,805 1,000,000 1,000,000 On-Market Acquisition Part 2 – Change of director’s interests in contracts Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part. Detail of contract N/A Nature of interest N/A Name of registered holder (if issued securities) N/A Date of change N/A No. and class of securities to which N/A interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed Interest acquired N/A Interest disposed N/A Value/Consideration N/A Interest after change N/A Note: If consideration is non-cash, provide details and an estimated valuation Part 3 – +Closed period Were the interests in the securities or contracts detailed above No traded during a +closed period where prior written clearance was required? If so, was prior written clearance provided to allow the trade to N/A proceed during this period? If prior written clearance was provided, on what date was this N/A provided? The CFO Solution + See chapter 19 for defined terms. Appendix 3Y Page 2 01/01/2011